C4 Therapeutics (CCCC) Competitors $4.05 -0.10 (-2.41%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CCCC vs. ALEC, INBX, CGEN, APLT, AVDL, ZYME, SEPN, COGT, BCAX, and BCYCShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Alector (ALEC), Inhibrx (INBX), Compugen (CGEN), Applied Therapeutics (APLT), Avadel Pharmaceuticals (AVDL), Zymeworks (ZYME), Septerna (SEPN), Cogent Biosciences (COGT), Bicara Therapeutics (BCAX), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. Alector Inhibrx Compugen Applied Therapeutics Avadel Pharmaceuticals Zymeworks Septerna Cogent Biosciences Bicara Therapeutics Bicycle Therapeutics C4 Therapeutics (NASDAQ:CCCC) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations. Which has higher valuation and earnings, CCCC or ALEC? Alector has higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$33.67M8.49-$132.49M-$1.70-2.38Alector$61.51M5.79-$130.39M-$1.70-2.14 Which has more volatility & risk, CCCC or ALEC? C4 Therapeutics has a beta of 3.04, indicating that its stock price is 204% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Do insiders & institutionals have more ownership in CCCC or ALEC? 78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 8.6% of C4 Therapeutics shares are held by insiders. Comparatively, 9.1% of Alector shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to CCCC or ALEC? In the previous week, C4 Therapeutics had 5 more articles in the media than Alector. MarketBeat recorded 7 mentions for C4 Therapeutics and 2 mentions for Alector. Alector's average media sentiment score of 1.05 beat C4 Therapeutics' score of 0.57 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alector 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CCCC or ALEC more profitable? Alector has a net margin of -257.54% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-313.35% -42.45% -27.55% Alector -257.54%-108.77%-27.03% Do analysts recommend CCCC or ALEC? C4 Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 146.91%. Alector has a consensus price target of $20.67, indicating a potential upside of 468.55%. Given Alector's stronger consensus rating and higher probable upside, analysts plainly believe Alector is more favorable than C4 Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Alector 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CCCC or ALEC? Alector received 126 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 61.54% of users gave Alector an outperform vote while only 38.24% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformC4 TherapeuticsOutperform Votes2638.24% Underperform Votes4261.76% AlectorOutperform Votes15261.54% Underperform Votes9538.46% SummaryAlector beats C4 Therapeutics on 13 of the 17 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$285.89M$2.94B$5.05B$8.87BDividend YieldN/A1.89%4.97%4.06%P/E Ratio-2.3821.3797.3414.18Price / Sales8.49382.101,218.4289.42Price / CashN/A160.1133.5132.79Price / Book1.004.195.805.12Net Income-$132.49M-$41.63M$119.07M$225.99M7 Day Performance-14.19%-4.73%-1.83%-1.32%1 Month Performance-35.20%-6.53%-3.64%0.60%1 Year Performance173.65%25.63%31.62%26.23% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics2.6434 of 5 stars$4.05-2.4%$10.00+146.9%+139.6%$285.89M$33.67M-2.38150Analyst ForecastALECAlector4.4456 of 5 stars$3.64-5.7%$20.67+468.5%-26.1%$355.99M$61.51M-2.23270Positive NewsINBXInhibrx1.2884 of 5 stars$14.04-1.7%N/A-36.9%$206.86M$1.63M0.00166CGENCompugen2.7226 of 5 stars$1.43-0.7%$4.00+179.7%+121.5%$127.61M$59.85M71.5068APLTApplied Therapeutics4.3431 of 5 stars$9.43+5.6%$12.50+32.6%+373.9%$1.10B$9.99M-5.8330AVDLAvadel Pharmaceuticals2.3424 of 5 stars$10.75+0.3%$24.43+127.2%-7.5%$1.03B$138.16M-13.61154Short Interest ↓ZYMEZymeworks2.8655 of 5 stars$14.55-1.5%$19.00+30.6%+74.0%$1.02B$76.01M0.00290SEPNSepternaN/A$22.50-7.0%$43.67+94.1%N/A$1.02BN/A0.00N/AAnalyst ForecastNews CoverageGap UpCOGTCogent Biosciences2.866 of 5 stars$9.08+0.2%$14.83+63.4%+20.6%$1.00BN/A0.0080Analyst RevisionBCAXBicara Therapeutics3.1692 of 5 stars$18.38-4.9%$43.33+135.8%N/A$1.00BN/A0.0032Analyst RevisionBCYCBicycle Therapeutics2.8495 of 5 stars$20.36-0.6%$40.13+97.1%+49.4%$968.12M$26.98M-6.19240Analyst Revision Related Companies and Tools Related Companies Alector Competitors Inhibrx Competitors Compugen Competitors Applied Therapeutics Competitors Avadel Pharmaceuticals Competitors Zymeworks Competitors Septerna Competitors Cogent Biosciences Competitors Bicara Therapeutics Competitors Bicycle Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CCCC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
